Apollo Endosurgery Announces Publication of Outcomes of Endoscopic Sleeve Gastroplasty (ESG) in 1,000 Consecutive Patients

AUSTIN, Texas–(BUSINESS WIRE)–Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in
less invasive medical devices for bariatric and gastrointestinal
procedures, announced the publication of Outcomes of Endoscopic
Gastroplasty (“ESG”) in 1,000 Consecutive Patients from a single center
– King Saud University, Riyadh, Saudi Arabia featured in Gastrointestinal
(GIE) – https://doi.org/10.1016/j.gie.2018.12.012.

ESG is an endoscopic minimally invasive weight loss procedure based on
full-thickness endoscopic suturing using Apollo’s OverStitch™ device. In
the ESG procedure, a series of sutures are placed through the gastric
wall reducing the stomach volume by 80% creating a restrictive
endoscopic sleeve. The result allows a patient to consume less food and
remain satiated longer.

“Our experience has been that patients find the ESG procedure very
appealing and for our practice it is now an established option for our
patients. In these first 1,000 consecutive patients that we treated with
Endoscopic Sleeve Gastroplasty, patients experienced a 100% remission
for hypertension related comorbidities, a 70% remission rate for type 2
diabetes with the remaining 30% showing significant improvement, and we
confirmed that ESG is a safe, well-tolerated, and effective procedure.
In addition, we also achieved 64.7% excess weight loss at 18 months
follow-up, which is comparable to results achieved with other surgical
bariatric interventions,” said Dr. Aayed AlQahtani, Professor of Surgery
at King Khalid University Hospital and Director of Obesity Chair at King
Saud University.

Key data reported from the 1,000 patients who underwent the ESG
procedure include:

  • Mean age was 34.4 ±9.5 years, and mean BMI was 33.3 ±4.5 kg/m2
  • Mean % total weight loss at 18 months was 14.8 ±8.5%
  • Significant impact to obesity related comorbidities occurred by month

    • 13 of 17 cases of type 2 diabetes were in complete remission
    • All 28 cases of hypertension were in complete remission
    • 18 of 32 cases of dyslipidemia were in complete remission
  • 24 (2.4%) patients were admitted to the hospital due to postoperative
    complaints. No patient required an emergency intervention and there
    were no mortalities.

About OverStitch

The OverStitch endoscopic suturing system enables advanced endoscopic
surgery by allowing physicians to place full-thickness sutures from a
flexible endoscope. This new technology enables a secure approximation
of tissue endoscopically and a wide range of less invasive solutions for
physicians who treat defects in both the upper and lower GI tract of
their patients. Additionally, physicians are leveraging endoscopic
suturing to perform a variety of advanced bariatric procedures. For more
information regarding OverStitch go to: www.apolloendo.com.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less
invasive therapies to treat various gastrointestinal conditions, ranging
from gastrointestinal defect repairs to the interventional treatment of
obesity. Apollo’s device based therapies are an alternative to invasive
surgical procedures, thus lowering complication rates and reducing total
healthcare costs. Apollo’s products are offered in over 70 countries
today and include the OverStitch™ Endoscopic Suturing System, the
OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric

Apollo’s common stock is traded on Nasdaq Global Market under the symbol
“APEN.” For more information regarding Apollo, go to: www.apolloendo.com.

© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party
trademarks used herein are the property of their respective owners.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements
that are subject to risks and uncertainties that could cause results to
be materially different than expectations. Important factors that could
cause actual results to differ materially include: reports of adverse
events related to our products, developments in medical technology,
regulatory approvals and extensive regulatory oversight by the FDA or
other regulatory bodies, unfavorable media coverage related to our
products or related procedures, reimbursement decisions by private or
government payors, physician adoption and recommendations of procedures
utilizing our products and other factors detailed from time to time in
the reports Apollo files with the Securities and Exchange Commission, or
SEC, including its Form 10-K for the year ended December 31, 2017, and
its Form 10-Q for the three months ended September 30, 2018. Copies of
reports filed with the SEC are posted on Apollo’s website and are
available from Apollo without charge. These forward-looking statements
are not guarantees of future performance and speak only as of the date
hereof, and, except as required by law, Apollo disclaims any obligation
to update these forward-looking statements to reflect future events or


Media Contact:
Jen Cook, 512-279-5158
[email protected]

Investor Contacts:
John Gillings, 512-279-5100
Relations Manager
[email protected]

error: Content is protected !!